GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1)Patients with Stage III/IV NSCLC on treatment with anti-PD-1/PD-L1 (ICI)+/ -chemotherapy. 2) Patients who have measurable disease including a lesion that is amenable to injection. 3) Patients who are able and willing to undergo a pre-treatment and on-treatment biopsy.

You may not be eligible for this study if the following are true:

  • 1) Patients with a history of severe hypersensitivity reaction to ICI. 2) Patients who require ongoing therapy with systemic immunosuppressive drugs including systemic corticosteroids. 3) Patients with a history of active autoimmune disease requiring treatment in the past 2 years.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.